Sign Out
Gastrointestinal disorders: Common: Dry mouth. Uncommon: Abdominal pain.
General disorders and administration site conditions: Common: Fatigue. Uncommon: Asthenia.
Post Marketing Data: Immune system disorders: Not known: Hypersensitivity including anaphylaxis.
Metabolism and nutrition disorders: Not known: Increased weight, increased appetite.
Psychiatric disorders: Not known: Aggression, agitation, hallucination, depression, insomnia, suicidal ideation, nightmares.
Nervous system disorders: Not known: Convulsions, paraesthesia, dizziness, syncope, tremor, dysgeusia.
Eyes disorders: Not known: Visual disturbances, blurred vision, oculogyration.
Ear and labyrinth disorders: Not known: Vertigo.
Cardiac disorders: Not known: Palpitations, tachycardia.
Respiratory, thoracic, and mediastinal disorders: Not known: Dyspnea.
Gastrointestinal disorders: Not known: Nausea, vomiting, diarrhea.
Hepatobiliary disorders: Not known: Hepatitis, abnormal liver function test.
Skin and subcutaneous tissue disorders: Not known: Angioneurotic edema, fixed drug eruption, pruritus, rash, urticaria.
Musculoskeletal and connective tissues disorders: Not known: Myalgia, arthralgia.
Renal and urinary disorders: Not known: Dysuria, urinary retention.
General disorders and administration site conditions: Not known: Edema.
Skin reactions occurring after discontinuation of Levocetirizine: After Levocetirizine discontinuation, pruritus has been reported (see Warnings and Precaution).
View ADR Monitoring Form
